The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis

Journal of Anatomy

Volumn 224, Issue 1, 2014, Pages 29-35

  Koneczny, Inga ^a   Cossins, Judith ^a   Vincent, Angela ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

AChR; DOK7; IgG4; LRP4; MG; Muscle specific tyrosine kinase; Myasthenia gravis; Neuromuscular transmission; Quantal content; RAPSN

Indexed keywords

HLA A2 ANTIGEN; HLA A25 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR14 ANTIGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; MUSCLE SPECIFIC TYROSINE KINASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGENIC MODULATION; BULBAR PARALYSIS; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; HUMAN; IMMUNOPATHOLOGY; MINIATURE ENDPLATE POTENTIAL; MOTONEURON; MUSCLE INNERVATION; MYASTHENIA GRAVIS; NERVE CELL DIFFERENTIATION; NERVE ENDING; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ACHR; DOK7; IGG4; LRP4; MG; MUSCLE-SPECIFIC TYROSINE KINASE; MYASTHENIA GRAVIS; NEUROMUSCULAR TRANSMISSION; QUANTAL CONTENT; RAPSN;

AUTOANTIBODIES; HUMANS; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC;

EID: 84890190765     PISSN: 00218782     EISSN: 14697580     Source Type: Journal    
DOI: 10.1111/joa.12034     Document Type: Review

References (87)

1. Arber S, Burden SJ, Harris AJ (2002) Patterning of skeletal muscle. Curr Opin Neurobiol 12, 100-103.
2. ter Beek WP, Martinez-Martinez P, Losen M, et al. (2009) The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. Am J Pathol 175, 1536-1544.
3. Bergamin E, Hallock PT, Burden SJ, et al. (2010) The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization. Mol Cell 39, 100-109.
4. Burden SJ (2002) Building the vertebrate neuromuscular synapse. J Neurobiol 53, 501-511.
5. Burden SJ (2011) SnapShot: neuromuscular junction. Cell 144, 826-826.e1.
6. Burden SJ, Depalma RL, Gottesman GS (1983) Crosslinking of proteins in acetylcholine receptor-rich membranes: association between the beta-subunit and the 43 kd subsynaptic protein. Cell 35, 687-692.
7. Burges J, Vincent A, Molenaar PC, et al. (1994) Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 17, 1393-1400.
8. Burgess RW, Skarnes WC, Sanes JR (2000) Agrin isoforms with distinct amino termini: differential expression, localization, and function. J Cell Biol 151, 41-52.
9. Carr AS, Cardwell CR, McCarron PO, et al. (2010) A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 10, 46.
10. Chang T, Gunaratne P, Gamage R, et al. (2009) MuSK-antibody-positive myasthenia gravis in a South Asian population. J Neurol Sci 284, 33-35.
11. Cole RN, Reddel SW, Gervasio OL, et al. (2008) Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 63, 782-789.
12. Cole RN, Ghazanfari N, Ngo ST, et al. (2010) Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J Physiol 588, 3217-3229.
13. Compston DA, Vincent A, Newsom-Davis J, et al. (1980) Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103, 579-601.
14. Cossins J, Belaya K, Zoltowska K, et al. (2012) The search for new antigenic targets in myasthenia gravis. Ann N Y Acad Sci 1275, 123-128.
15. DeChiara TM, Bowen DC, Valenzuela DM, et al. (1996) The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85, 501-512.
16. Evoli A, Tonali PA, Padua L, et al. (2003) Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126, 2304-2311.
17. Evoli A, Bianchi MR, Riso R, et al. (2008) Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci 1132, 76-83.
18. Farrugia ME, Robson MD, Clover L, et al. (2006) MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 129, 1481-1492.
19. Farrugia ME, Bonifati DM, Clover L, et al. (2007) Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. J Neuroimmunol 185, 136-144.
20. Ferns MJ, Campanelli JT, Hoch W, et al. (1993) The ability of agrin to cluster AChRs depends on alternative splicing and on cell surface proteoglycans. Neuron 11, 491-502.
21. Finlayson S, Palace J, Beeson D (in press) Congenital myasthenic syndromes: an update. Pract Neurol.
22. Gautam M, Noakes PG, Mudd J, et al. (1995) Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice. Nature 377, 232-236.
23. Glass DJ, Bowen DC, Stitt TN, et al. (1996) Agrin acts via a MuSK receptor complex. Cell 85, 513-523.
24. Gomez AM, Van Den Broeck J, Vrolix K, et al. (2010) Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity 43, 353-370.
25. Guptill JT, Sanders DB (2010) Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 23, 530-535.
26. Guptill JT, Sanders DB, Evoli A (2011) Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 44, 36-40.
27. Hallock PT, Xu CF, Park TJ, et al. (2010) Dok-7 regulates neuromuscular synapse formation by recruiting Crk and Crk-L. Genes Dev 24, 2451-2461.
28. Herbst R, Burden SJ (2000) The juxtamembrane region of MuSK has a critical role in agrin-mediated signaling. EMBO J 19, 67-77.
29. Higuchi O, Hamuro J, Motomura M, et al. (2011) Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69, 418-422.
30. Hoch W, McConville J, Helms S, et al. (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7, 365-368.
31. Hopf C, Hoch W (1998) Dimerization of the muscle-specific kinase induces tyrosine phosphorylation of acetylcholine receptors and their aggregation on the surface of myotubes. J Biol Chem 273, 6467-6473.
32. Illa I, Diaz-Manera JA, Juarez C, et al. (2005) ['Seronegative' myasthenia gravis and antiMuSK positive antibodies: description of Spanish series]. Med Clin 125, 100-102.
33. Jha S, Xu K, Maruta T, et al. (2006) Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol 175, 107-117.
34. Karmouch J, Dobbertin A, Sigoillot S, et al. (2012) Developmental consequences of the ColQ/MuSK interactions. Chem Biol Interact, doi: 10.1016/j.cbi.2012.10.006.
35. Kim N, Burden SJ (2008) MuSK controls where motor axons grow and form synapses. Nat Neurosci 11, 19-27.
36. Kim N, Stiegler AL, Cameron TO, et al. (2008) Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 135, 334-342.
37. Klooster R, Plomp JJ, Huijbers MG, et al. (2012) Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 135, 1081-1101.
38. Kummer TT, Misgeld T, Sanes JR (2006) Assembly of the postsynaptic membrane at the neuromuscular junction: paradigm lost. Curr Opin Neurobiol 16, 74-82.
39. LaRochelle WJ, Froehner SC (1986) Determination of the tissue distributions and relative concentrations of the postsynaptic 43-kDa protein and the acetylcholine receptor in Torpedo. J Biol Chem 261, 5270-5274.
40. Lee JY, Sung JJ, Cho JY, et al. (2006) MuSK antibody-positive, seronegative myasthenia gravis in Korea. J Clin Neurosci 13, 353-355.
41. Lin W, Burgess RW, Dominguez B, et al. (2001) Distinct roles of nerve and muscle in postsynaptic differentiation of the neuromuscular synapse. Nature 410, 1057-1064.
42. Lin W, Dominguez B, Yang J, et al. (2005) Neurotransmitter acetylcholine negatively regulates neuromuscular synapse formation by a Cdk5-dependent mechanism. Neuron 46, 569-579.
43. McConville J, Farrugia ME, Beeson D, et al. (2004) Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 55, 580-584.
44. McMahan UJ (1990) The agrin hypothesis. Cold Spring Harb Symp Quant Biol 55, 407-418.
45. Misgeld T, Kummer TT, Lichtman JW, et al. (2005) Agrin promotes synaptic differentiation by counteracting an inhibitory effect of neurotransmitter. Proc Natl Acad Sci U S A 102, 11088-11093.
46. Mori S, Kubo S, Akiyoshi T, et al. (2012a) Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol 180, 798-810.
47. Mori S, Yamada S, Kubo S, et al. (2012b) Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis. J Neuroimmunol 244, 1-7.
48. Morsch M, Reddel SW, Ghazanfari N, et al. (2012) Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors. Exp Neurol 237, 286-295.
49. Mossman S, Vincent A, Newsom-Davis J (1988) Passive transfer of myasthenia gravis by immunoglobulins: lack of correlation between AChR with antibody bound, acetylcholine receptor loss and transmission defect. J Neurol Sci 84, 15-28.
50. Motomura M (2011) [The pathophysiology and treatment of autoimmune neuromuscular junction diseases]. Rinsho Shinkeigaku 51, 872-876.
51. Motomura M, Higuchi O (2012) Progress of myasthenia gravis: discovery of Lrp4 antibodies. Rinsho Shinkeigaku 52, 1303-1305.
52. Nemoto Y, Kuwabara S, Misawa S, et al. (2005) Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry 76, 714-718.
53. van der Neut Kolfschoten M, Schuurman J, Losen M, et al. (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317, 1554-1557.
54. Niks EH, Kuks JB, Roep BO, et al. (2006) Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 66, 1772-1774.
55. Niks EH, Kuks JB, Verschuuren JJ (2007) Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands. J Neurol Neurosurg Psychiatry 78, 417-418.
56. Niks EH, Kuks JB, Wokke JH, et al. (2010) Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia. Muscle Nerve 42, 283-288.
57. Oh SJ (2009) Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status. J Clin Neurol 5, 53-64.
58. Oh SJ, Hatanaka Y, Hemmi S, et al. (2006) Repetitive nerve stimulation of facial muscles in MuSK antibody-positive myasthenia gravis. Muscle Nerve 33, 500-504.
59. Ohta K, Shigemoto K, Fujinami A, et al. (2007) Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol 14, 1029-1034.
60. Okada K, Inoue A, Okada M, et al. (2006) The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 312, 1802-1805.
61. Pevzner A, Schoser B, Peters K, et al. (2012) Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 259, 427-435.
62. Plomp JJ, Van Kempen GT, De Baets MB, et al. (1995) Acetylcholine release in myasthenia gravis: regulation at single end-plate level. Ann Neurol 37, 627-636.
63. Punga AR, Ruegg MA (2012) Signaling and aging at the neuromuscular synapse: lessons learnt from neuromuscular diseases. Curr Opin Pharmacol 12, 340-346.
64. Richman DP (2012) Antibodies to low density lipoprotein receptor-related protein 4 in seronegative myasthenia gravis. Arch Neurol 69, 434-435.
65. Sanders DB, El-Salem K, Massey JM, et al. (2003) Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60, 1978-1980.
66. Sanes JR, Lichtman JW (2001) Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat Rev Neurosci 2, 791-805.
67. Scuderi F, Marino M, Colonna L, et al. (2002) Anti-p110 autoantibodies identify a subtype of 'seronegative' myasthenia gravis with prominent oculobulbar involvement. Lab Invest 82, 1139-1146.
68. Selcen D, Fukuda T, Shen XM, et al. (2004) Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 62, 1945-1950.
69. Shigemoto K, Kubo S, Maruyama N, et al. (2006) Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 116, 1016-1024.
70. Shigemoto K, Kubo S, Jie C, et al. (2008) Myasthenia gravis experimentally induced with muscle-specific kinase. Ann N Y Acad Sci 1132, 93-98.
71. Shiraishi H, Motomura M, Yoshimura T, et al. (2005) Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 57, 289-293.
72. Stickler DE, Massey JM, Sanders DB (2005) MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol 116, 2065-2068.
73. Viegas S, Jacobson L, Waters P, et al. (2012) Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp Neurol 234, 506-512.
74. Vincent A (2002) Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2, 797-804.
75. Vincent A, McConville J, Farrugia ME, et al. (2003) Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci 998, 324-335.
76. Weatherbee SD, Anderson KV, Niswander LA (2006) LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. Development 133, 4993-5000.
77. Wu H, Xiong WC, Mei L (2010) To build a synapse: signaling pathways in neuromuscular junction assembly. Development 137, 1017-1033.
78. Wu H, Lu Y, Shen C, et al. (2012) Distinct roles of muscle and motoneuron LRP4 in neuromuscular junction formation. Neuron 75, 94-107.
79. Yang X, Li W, Prescott ED, et al. (2000) DNA topoisomerase IIbeta and neural development. Science 287, 131-134.
80. Yang X, Arber S, William C, et al. (2001) Patterning of muscle acetylcholine receptor gene expression in the absence of motor innervation. Neuron 30, 399-410.
81. Yumoto N, Kim N, Burden SJ (2012) Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature 489, 438-442.
82. Zhang B, Luo S, Wang Q, et al. (2008) LRP4 serves as a coreceptor of agrin. Neuron 60, 285-297.
83. Zhang W, Coldefy AS, Hubbard SR, et al. (2011) Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (MuSK). J Biol Chem 286, 40624-40630.
84. Zhang B, Tzartos JS, Belimezi M, et al. (2012) Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 69, 445-451.
85. Zhu D, Yang Z, Luo Z, et al. (2008) Muscle-specific receptor tyrosine kinase endocytosis in acetylcholine receptor clustering in response to agrin. J Neurosci 28, 1688-1696.
86. Zong Y, Jin R (2012) Structural mechanisms of the agrin-LRP4-MuSK signaling pathway in neuromuscular junction differentiation. Cell Mol Life Sci, doi: 10.1007/s00018-012-1209-9.
87. Zong Y, Zhang B, Gu S, et al. (2012) Structural basis of agrin-LRP4-MuSK signaling. Genes Dev 26, 247-258.